Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ije/dyg193 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Criminalizing public space through a decriminalization framework: The paradox of British Columbia, Canada.
Int J Drug Policy
December 2024
Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; Stop the Sweeps, Vancouver, BC, Canada.
This commentary explores a recent shift in British Columbia's drug policy under a novel drug "decriminalization" framework. We focus on the province's move toward "recriminalization" under this framework. In short, recriminalization was a shift in BC's drug decriminalization framework to only apply in private residences, and be removed from essentially all outdoor spaces.
View Article and Find Full Text PDFWine consumption and cardiovascular health: the unresolved French paradox and the promise of objective biomarkers.
Eur Heart J
January 2025
Department of Epidemiology and Prevention, IRCCS NEUROMED, Via dell'Elettronica, 86077 Pozzilli, Italy.
Approaching the paradoxical relationship between hypertensive disorders of pregnancy and cerebral palsy among infants born very preterm with very low birth weight.
Hypertens Res
January 2025
Department of Preventive Medicine and Public Health, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
The partner paradox: How can we better understand shared cognitive decline in couples?
J Alzheimers Dis
November 2024
Center for Health Outcomes and Interdisciplinary Research, Massachusetts General Hospital, Boston, MA, USA.
Shared cognitive decline among spouses remains in the early stages of being understood. In this commentary, we discuss Meng et al.'s systematic review and meta-analysis, which synthesizes the evidence for concordance of cognitive decline in couples.
View Article and Find Full Text PDFDoes Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary.
Rheumatol Ther
December 2024
Service de Rhumatologie, Hôpital Cochin, AP-HP Centre-Université Paris Cité, 75014, Paris, France.
This commentary explores the potential cardiovascular (CV) benefits of combining methotrexate (MTX) and Janus kinase inhibitors (JAKis) in the treatment of rheumatoid arthritis (RA). While European guidelines recommend MTX as first-line treatment, concerns about the CV risks associated with JAKis have emerged. This article reviews the existing literature to assess the role of concomitant MTX in reducing CV risk when used with JAKis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!